Ublituximab (Briumvi) for Early Forms of Relapsing Multiple Sclerosis

Abroad (travel likely)RecruitingPHASE4

Conditions

Multiple Sclerosis · Multiple Sclerosis (MS) - Relapsing-remitting

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Northwestern Memorial Hospital, Chicago, Illinois, United States
Contact: Study coordinator (Caroline Gebczak, B.S.) · caroline.gebczak@northwestern.edu · 630-313-0470
Contact: Study coordinator (Dylan Rice, B.A.) · dylan.rice@northwestern.edu · 240-362-4800
Contact: Principal Investigator (Farrah J Mateen, MD, PhD)

Study leads

Farrah J Mateen, MD, PhD
Principal Investigator
Northwestern University

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

A Study to Evaluate Pharmacokinetics (PK) and Safety of Subcutaneous (SC) Ublituximab Administered at Various Injection Sites and Relative Bioavailability Via Autoinjector (AI) Versus Syringe Subcutaneously in Participants With Multiple Sclerosis (MS)

Multiple Sclerosis

Abroad (travel likely)RecruitingPHASE2

Bihać, Bosnia and Herzegovina · Sarajevo, Bosnia and Herzegovina

Silodosin for Urinary Symptoms in Female Patients With Multiple Sclerosis

Multiple Sclerosis · Lower Urinary Track Symptoms

Abroad (travel likely)RecruitingPHASE4

Morristown, United States

Magnetic Resonance Imaging (MRI) to Evaluate Activity of Multiple Sclerosis (MS)

Multiple Sclerosis

Abroad (travel likely)Recruiting

Bethesda, United States

Auditory Functions in Patients With Multiple Sclerosis

Multiple Sclerosis · Hearing Disorders

Abroad (travel likely)Recruiting

Catania, Italy